Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis
Tsutomu Takeuchi(Keio University), Takayoshi Koike(Hokkaido University), Shigeko Inokuma(Tokyo Metropolitan Komagome Hospital), Juhee Ryu(Nihon University), Hisashi Yamanaka(Tokyo Women's Medical University), Yoshihiko Tatsuki, Naoki Ishiguro(Aichi Developmental Disability Center), Harumi Kondo(Kitasato University Medical Center), Yashiro Nogami, Naoyuki Kamatani(Genetic Analysis (Norway)), T. Ochi(National Sagamihara Hospital), Masayoshi Harigai(Tokyo Women's Medical University), Kazuhiko Inoue(Tokyo Women's Medical University Adachi Medical Center), Yoshiya Tanaka(University of Occupational and Environmental Health Japan)
Cited by 413
Related Papers
International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
|Journal of Thrombosis and Haemostasis|2006|7.1k
Trial of Anifrolumab in Active Systemic Lupus Erythematosus
|New England Journal of Medicine|2019|1.3k
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
|Annals of the Rheumatic Diseases|2023|913
Nitrogen and phosphorus constrain the CO2 fertilization of global plant biomass
|Nature Climate Change|2019|528